WO2013004716A9 - Peptide beads - Google Patents

Peptide beads Download PDF

Info

Publication number
WO2013004716A9
WO2013004716A9 PCT/EP2012/062963 EP2012062963W WO2013004716A9 WO 2013004716 A9 WO2013004716 A9 WO 2013004716A9 EP 2012062963 W EP2012062963 W EP 2012062963W WO 2013004716 A9 WO2013004716 A9 WO 2013004716A9
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
peptide
beads
peptide beads
biotin
Prior art date
Application number
PCT/EP2012/062963
Other languages
French (fr)
Other versions
WO2013004716A1 (en
Inventor
Dirk De Bruyn Ouboter
Thomas Schuster
Vijay SHANKER
Wolfgang Meier
Original Assignee
Universität Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Basel filed Critical Universität Basel
Publication of WO2013004716A1 publication Critical patent/WO2013004716A1/en
Publication of WO2013004716A9 publication Critical patent/WO2013004716A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to peptide beads comprising amphiphilic bead-forming peptides of the formula R1 (A1)k (A2 D-A3)m (A2)n (A1)l R2, wherein R1 is an amino acid, biotin, an acyl group or hydrogen, R2 is NH2, OH, alkoxy, hydroxyethylamide or an optionally amidated amino acid, or biotin; A1 is a hydrophilic L-amino acid; A2 is an aromatic L-amino acid; A3 is an aliphatic D-amino acid; k and l are, independently of each other, between 0 and 12; m is between 2 and 8; and n is 0 or 1; a mediator peptide of the formula R1 (A1)k (A2 D-A3)m (A2)n (A1)l R2, wherein at least one of the substituents R1, R2 and/or at least one of the amino acids A1 is different from the corresponding substituents R1, R2 and/or amino acids A1 in the peptide forming the peptide beads; and a payload, such as RNA, DNA or hydrophilic drug, furthermore to the use of such peptide beads for the delivery of an active pharmaceutical ingredient into tissue and cells, and the release of the active pharmaceutical ingredient in the tissue or cell causing the desired therapeutic effect.
PCT/EP2012/062963 2011-07-04 2012-07-04 Peptide beads WO2013004716A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11172558 2011-07-04
EP11172558.6 2011-07-04

Publications (2)

Publication Number Publication Date
WO2013004716A1 WO2013004716A1 (en) 2013-01-10
WO2013004716A9 true WO2013004716A9 (en) 2013-04-11

Family

ID=46458518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/062963 WO2013004716A1 (en) 2011-07-04 2012-07-04 Peptide beads

Country Status (1)

Country Link
WO (1) WO2013004716A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (en) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, Related Compounds and Uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP5860698B2 (en) 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use
BRPI0920209A2 (en) 2008-10-15 2015-12-22 Angiochem Inc conjugates of glp-1 agonists and their uses
RU2531591C2 (en) 2008-10-15 2014-10-20 Ангиокем Инк. Etoposide and doxorubicin conjugates for drug delivery
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (en) 2008-12-17 2011-09-27 Angiochem Inc Membrane type-1 matrix metalloprotein inhibitors and uses thereof.
ES2729261T3 (en) 2009-04-20 2019-10-31 Angiochem Inc Ovarian cancer treatment using an anticancer agent conjugated to an Angiopep-2 analog
IN2012DN00248A (en) 2009-07-02 2015-05-01 Angiochem Inc
EP3142964B1 (en) * 2014-05-13 2021-12-22 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Peptide-polypeptide co-assembled nanoparticles for drug delivery
KR101580051B1 (en) * 2014-08-04 2015-12-23 국민대학교산학협력단 Amphiphilic polymer
ES2826827T3 (en) 2015-06-15 2021-05-19 Angiochem Inc Methods for the treatment of leptomeningeal carcinomatosis
GB202013940D0 (en) * 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CN115703890A (en) * 2021-08-09 2023-02-17 上海其胜生物制剂有限公司 Super-elastic transparent gel and preparation method thereof

Also Published As

Publication number Publication date
WO2013004716A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
WO2013004716A9 (en) Peptide beads
EP2594582A3 (en) Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens
EP3756690A3 (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
JP2015510393A5 (en)
WO2008039483A3 (en) Modified self-assembling peptides
WO2010100477A3 (en) Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
KR20130043625A (en) Compounds and their use
WO2007043048A3 (en) Self-assembled fmoc-ff hydrogels
WO2012048854A3 (en) Formulation suitable for stabilizing proteins, which is free of mammalian excipients
UA100127C2 (en) Peptide cdh3 and drug containing it
WO2009028824A3 (en) A novel cationic lipid, a preparation method of the same and a delivery system comprising the same
WO2013096958A8 (en) Compositions and methods for the delivery of biologically active rnas
WO2011053065A3 (en) Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same
EP2481748A3 (en) Foxp3 peptide vaccine
US20150141324A1 (en) Stable peptide-based furin inhibitors
WO2012173994A3 (en) Phase changing formulations of nucleic acid payloads
WO2010057275A8 (en) Cyclic peptides and uses thereof
JP2008518622A5 (en)
RU2012146542A (en) METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL CELLS AND IN PEOPLE
Wang et al. Engineered mRNA delivery systems for biomedical applications
WO2007089950A3 (en) Preparations of growth hormone
WO2010059829A3 (en) Compositions and methods for triggered release rna therapeutics
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides
WO2009005798A3 (en) Antifungal formulation and method of preparation
WO2013072686A3 (en) Self-assembling peptides and hydrogels comprising them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12732647

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12732647

Country of ref document: EP

Kind code of ref document: A1